It is possible that with a combination approach, anti-tumor immune responses are further enhanced by non-redundant targeting of the PD-1/PD-L1 and CTLA-4 signaling axes, or by specific tumor mutational features that benefit from CTLA-4 inhibition. This evidence concerns the gene CD274 and neoplasm.